Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 17, 2013
Reporting Period: First Quarter 2013
This filing announces the results of operations for the first quarter of 2013. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a notification of the results rather than a detailed financial statement.
Non-GAAP Measures Discussed: The company utilizes non-GAAP financial measures, including net earnings and diluted earnings per share excluding specified items. These adjustments account for:
- Costs related to the separation of the research-based pharmaceuticals business.
- Litigation reserves and acquired in-process research and development.
- Milestone payments, restructuring, and integration costs.
- Cost reduction initiatives.
- Tax expense adjustments for 2013 U.S. tax law changes.
- Intangible amortization expense.
Material Changes and Comparisons
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year performance analysis.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide greater visibility on ongoing business performance and are used internally to monitor operations. However, the company cautions that these measures should be considered in addition to, not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing highlights the impact of the separation of the research-based pharmaceuticals business and changes in U.S. tax law as significant factors affecting reported results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2013 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures provided in the press release.
- Assess the specific financial impact of the research-based pharmaceuticals business separation.
- Confirm the details of the tax expense adjustment related to 2013 U.S. tax law changes.